Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019

March 1, 2012 - PRLog -- GlobalData’s analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.

The current competitive landscape consists mainly of interferon therapy and nucleoside analogues. Intron A (interferon alpha 2b) and Pegasys are the two approved interferon therapies for hepatitis B therapeutics. The nucleoside analogues include Viread, Baraclude, Hepsera (adevofir), Epivir-HBV/ Zeffix (lamivudine) and Tyzeka for the treatment of hepatitis B. Interefrons have a defined duration of therapy, while nucleosides sometimes require long-term therapy. Interferon therapy is contraindicated in patients with advanced cirrhosis, where as the nucleoside analogues have no such constraint. Also, nucleoside analogues have a higher anti-viral potency, however when rapid results are required, therapy with an interferon is preferred.

Pegasys was approved for the treatment of hepatitis B in 2005 in the Europe and US, in February and May respectively. It was approved in Japan in September, 2011 for the treatment of hepatitis B. Among nucleoside analogues, the US launch was witnessed for Hepsera in 2002, Baraclude in 2005, Sebivo in 2006 and Viread in 2008. Similarly, Tyzeka/Sebivo was launched in Europe in 2007, Hepsera in 2003, Viread in 2008 and Baraclude in 2006. In Japan, Hepsera was launched in 2002, Baraclude in 2006 and Viread in 2009.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


The unmet need is high in hepatitis B therapeutics market. This is primarily attributed to the development of resistance to the most commonly used nucleoside therapy for the treatment of hepatitis B. The interferons also due to their high cost pose a hindrance to the patients who cannot afford it. The safety issues with all the nucleoside analogues, which have led to black box warnings being issued by the Food and Drug Administration (FDA), are also a concern for the physicians. The high unmet need can also be attributed to the poor tolerability of patients to interferon therapy.

GlobalData, the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Hepa...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.